Imagen de Portada

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Samantha C. Shao, Joseph Hentz, Patti Shank, Michael Leonard, David W. Dodick, Todd J. Schwedt
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Headache: The Journal of Head and Face Pain
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
por: Andrew Blumenfeld, et al.
Publicado: (2024)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
por: Stephen D. Silberstein, et al.
Publicado: (2024)

A history of abuse is associated with more severe migraine‐ and pain‐related disability: Results from the American Registry for Migraine Research
por: Meesha Trivedi, et al.
Publicado: (2024)

The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
por: Dani C. Smith, et al.
Publicado: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
por: Chia‐Chun Chiang, et al.
Publicado: (2024)

Integrating gepants into clinical practice for the acute treatment of migraine
por: Richard B. Lipton, et al.
Publicado: (2026)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
por: David W. Dodick, et al.
Publicado: (2025)

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
por: Ghader Mohammadnezhad, et al.
Publicado: (2024)

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
por: Todd J. Schwedt, et al.
Publicado: (2025)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
por: Richard B. Lipton, et al.
Publicado: (2025)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
por: Lawrence C. Newman, et al.
Publicado: (2025)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
por: Muneto Tatsumoto, et al.
Publicado: (2024)

The role of stress in the comorbidity of migraine and other chronic primary pain
por: Shi‐Jie Zhao, et al.
Publicado: (2025)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
por: Richard B. Lipton, et al.
Publicado: (2025)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
por: Shuu‐Jiun Wang, et al.
Publicado: (2024)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
por: Kara S. Graves, et al.
Publicado: (2026)

Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project
por: Larry Charleston
Publicado: (2024)

Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine
por: Haley C. Cropper, et al.
Publicado: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
por: Jennifer Robblee, et al.
Publicado: (2024)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
por: Jessica Ailani, et al.
Publicado: (2026)

Memantine as a migraine prophylactic agent in adolescents: A retrospective analysis
por: M. Ismail K. Yousaf, et al.
Publicado: (2025)

Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine
por: Marie Raquin, et al.
Publicado: (2025)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
por: Jeffrey D. Sharon, et al.
Publicado: (2024)

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
por: Gabriel Paiva da Silva Lima, et al.
Publicado: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
por: Samuel K. Peasah, et al.
Publicado: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
por: Anna Gryglas‐Dworak, et al.
Publicado: (2024)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
por: Anna de Dios, et al.
Publicado: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
por: Delora E. Denney, et al.
Publicado: (2024)

Early effect of onabotulinumtoxinA on EEG ‐based functional connectivity in patients with chronic migraine: A pilot study
por: Matteo Conti, et al.
Publicado: (2024)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
por: Gerlinde Freimark, et al.
Publicado: (2025)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
por: Rebecca Lindsay, et al.
Publicado: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
por: Graham A. McLeod, et al.
Publicado: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
por: Geneviève Tourigny‐Ruel, et al.
Publicado: (2026)

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial
por: Stefanie Lysk, et al.
Publicado: (2025)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Publicado: (2025)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
por: Emmanuelle A. D. Schindler, et al.
Publicado: (2025)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
por: Nathaniel M. Schuster, et al.
Publicado: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
por: Rikki Mangrum, et al.
Publicado: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
por: Yunus Emre Meydanal, et al.
Publicado: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
por: Joaquín Borrás‐Blasco, et al.
Publicado: (2025)